DiaMedica Therapeutics DMAC 深 沪
等待开盘 09-08 09:30:00 美东时间
6.14
+0.770
+14.34%
华盛通- 最 高6.20
- 今 开5.52
- 成交量 75.46万股
- 最 低 5.5014
- 昨 收 5.37
- 总市值 2.63亿
- 52周最高 6.8184
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.19
- 委 比 21.30%
- 总股本 4288.35万
- 历史最高 10.88
- 量 比 2.20
- 振 幅 13.01%
- 历史最低 1.12
- 每 手 1
- 风险率 0.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多DiaMedica Therapeutics Advances with Positive Trials and Funding
Diamedica Therapeutics ( ($DMAC) ) has released its Q2 earnings. Here is a brea...
08-14 12:24
DiaMedica Therapeutics Q2 EPS $(0.18) Beats $(0.19) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 38.46 percent decrease over losses of $(0.13) per share
08-13 04:15
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Exploring DiaMedica Therapeutics's Earnings Expectations
DiaMedica Therapeutics (NASDAQ:DMAC) is set to give its latest quarterly earnin...
08-12 03:02
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer
DiaMedica Therapeutics (NASDAQ:DMAC) announced on Wednesday the appointment of Julie Krop as Chief Medical Officer (CMO), effective immediately. Krop will succeed Lorianne Masuoka, who has resigned ...
08-06 20:48
DiaMedica Announces $30.1M Private Placement for DM199
Diamedica Therapeutics ( ($DMAC) ) has shared an announcement. On July 21, 2025...
07-21 20:56
DiaMedica Therapeutics raises $30 million in private placement
DiaMedica Therapeutics (NASDAQ:DMAC) announced on Monday definitive agreements for a $30.1 million private placement of common shares led by current investors. Pursuant to the terms of the securities ...
07-21 20:27
美股大行评级 | 潜在涨幅163.16%！Craig-Hallum上调DiaMedica Therapeutics目标价至11美元，维持"买入"评级
今日重点评级关注：Craig-Hallum：维持DiaMedica Therapeutics"买入"评级，目标价从8美元升至11美元；花旗：维持Cogent Biosciences"买入"评级，目标价从15美元升至22美元
07-21 09:19
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11
Craig-Hallum analyst Chase Knickerbocker maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $8 to $11.
07-18 23:57
